Success Leaves Clues with Robin Bailey and Al McDonald

The episode contains some substantive insights about healthcare system friction and patient access challenges, particularly around prior authorization and the persistence of fax-based workflows. However, it relies heavily on anecdotal storytelling and personal narrative rather than systematic problem analysis. John's discussion of the 4,000-5,000 patient support program employees in Canada and the shift from physician-centric to patient-centric systems provides useful context, but most claims lack supporting data or metrics, and the conversation frequently circles back to broad principles rather than drilling into novel operational insights.

“The medication existed, the evidence was there, but the access wasn't.”

“if you help patients get what they need, that's good. But also you have to reduce the burden on the hcps and the healthcare professionals caring for them”

The guest articulates a patient-centric approach to healthcare problem-solving, which is not particularly novel in 2025. The core insight - that healthcare systems are broken because they lack information centralization and patient focus - is well-established. While John's specific experience moving from begging for compassionate supply to building digitization solutions is personal, the underlying framework (patient access barriers → need for coordination tools → business opportunity) is conventional healthcare startup thinking. The fax-to-digital transition observation is a reasonable critique but hardly contrarian.

“a truly patient centered system would be a system where all the people involved in a patient's care”

“the process breaks down in so many different spots”

John Leombruno is a credible operator with relevant depth: he has a PhD in pharmacoepidemiology, direct experience as a pharmacist at SickKids, founded and exited companies (Patient Direct Pharmacy and GMD Distribution acquired by McKesson), and is currently running OkRx. He has built multiple businesses at the healthcare-data-access intersection and brings both scientific credibility and entrepreneurial track record. This is solid for a B2B healthcare podcast, though he is not a household name or mega-exit founder.

“A healthcare entrepreneur with a PhD and pharmacoepidemiology from the University of Toronto and an MBA from Queens University”

“John has built and scaled companies at the intersection of health, healthcare data and patient access”

The episode lacks concrete metrics, numbers, and named examples to support claims. John mentions sending 'a quarter of a million faxes' in 2018 and reducing fax volume to 50%, but provides no current transaction volumes, customer counts, revenue figures, or adoption metrics for OkRx. He references specific drugs (Remicade, Enbrel) and institutions (SickKids, Greenshield), but avoids quantifying impact. The mention of a '2-year grant from the Canadian Medical Association' is vague on size and outcomes. Most claims about system inefficiency are illustrative rather than evidenced.

“that year before we sold my company and I was like, you know, maybe the fourth largest player in this industry, we sent out a quarter of a million faxes, right?”

“there's over like, I think four or five thousand employees in Canada trying to help all these patients out”

The hosts ask reasonable setup questions and allow the guest to develop his narrative, but there is minimal substantive push-back or deep drilling. Al and Robin let John speak at length without pressing on contradictions, timelines, or competitive positioning. When Al asks 'do you think things are improving or going backwards,' John gives a rambling non-answer about scope growth over 20 years, and neither host follows up with specificity. There are no challenging questions about trade-offs, unit economics, regulatory barriers, or why prior authorization hasn't been digitized faster by larger players. The conversation feels collaborative but intellectually soft.

“John, can we talk about your company for a second?”

“I'm just curious, if you look back in your career now, do you think that you can point to anything that maybe some entrepreneurs underestimate”